How Often Do You Need a Shingles Vaccine Booster?

No booster dose of the shingles vaccine is currently recommended. The standard Shingrix vaccination is a two-dose series, with the second shot given two to six months after the first, and that pair of doses is considered complete. Data tracking vaccinated adults for more than a decade show that protection remains strong, which is why health authorities have not added a third dose to the schedule. That said, the question of whether a booster will eventually be needed is still being studied, and the answer depends partly on your age and immune status.

The Two-Dose Series Is the Full Course

Shingrix, the recombinant zoster vaccine, replaced the older live vaccine (Zostavax) as the preferred option in the United States in 2017. Unlike its predecessor, which was a single shot, Shingrix requires two doses. The first primes the immune system, and the second, given two to six months later, locks in a stronger and more durable response. Both doses are necessary to reach the level of protection seen in clinical trials. A single dose on its own provides substantially less and shorter-lasting immunity.

A common source of confusion is that people hear “two doses” and assume one of them is a booster. It is not. The second dose is part of the primary series, not a follow-up given years later. Once you have received both shots, you are considered fully vaccinated, and no additional dose is part of current guidelines.

How Long Protection Lasts

Clinical trials and follow-up studies have now tracked Shingrix recipients for more than ten years. The vaccine’s effectiveness against shingles holds up well over that period, with immune markers remaining elevated far longer than they did with the old live vaccine. In real-world claims data from the United States, Shingrix showed an overall effectiveness of about 86%, with similar numbers in adults aged 50 to 79 and somewhat lower but still substantial protection in those 80 and older.¹

The durability of Shingrix is a meaningful improvement over Zostavax, which lost much of its punch within five to eight years. That rapid waning was one of the reasons the older vaccine was pulled from the market. Shingrix’s adjuvant system, which amplifies the immune response, is a large part of why it holds up better over time. Researchers continue to monitor long-term data, but so far the protection curve has not shown the steep drop that would trigger a booster recommendation.

Why a Booster Might Eventually Be Needed

Even though current data look encouraging, immunity does not last forever against any pathogen. The varicella-zoster virus that causes shingles stays dormant in your nerve cells for life, and the main thing keeping it in check is your immune system’s ongoing surveillance. As people age, their cellular immunity against the virus naturally declines, which is why shingles risk rises sharply after 50 and again after 70.² The question is whether vaccine-induced immunity will also fade enough to leave a gap.

Researchers studying immune markers after Shingrix have found that the fold rise in antibody levels after vaccination is a reliable predictor of how well the vaccine protects someone, while a single snapshot of antibody levels at one time point is much less informative.³ This distinction matters for future booster decisions. If researchers can track how the fold rise translates to real-world protection years down the road, they will have a clearer signal for when immunity has dropped enough to warrant another dose.

Health economists have already modeled what a booster strategy might look like. One study built a lifetime simulation comparing no booster against a booster given at various intervals after the first dose, for people vaccinated at ages 60, 70, and 80.⁴ The existence of these models shows that policymakers are thinking about the possibility, even if the clinical evidence has not yet triggered a recommendation.

Finishing the Series Matters More Than Worrying About a Booster

If you have already received both Shingrix doses, you are in the best position current medicine offers. But a surprisingly large number of people who get the first shot never come back for the second. Early real-world data showed that only about 70% of people completed the series within six months of their first dose, climbing to roughly 80% within a year.⁵ Among Medicare beneficiaries specifically, about one in four who started the series in 2018 did not get the second dose within six months.⁶

More recent data looking at adults newly eligible for the vaccine between 2018 and 2024 found that about 63% completed the series within six months and roughly 75% within a year.⁷ The reasons people skip the second dose range from out-of-pocket costs and scheduling hassles to being put off by side effects from the first shot.⁶ Whatever the reason, skipping dose two leaves you with meaningfully weaker protection than the full series provides.

If you got the first dose months or even years ago and never returned for the second, you do not need to start over. Current guidance says to simply get the second dose as soon as you can, regardless of how much time has passed. There is no maximum interval that resets the clock.

What If You Got the Old Zostavax Vaccine

If you received the live Zostavax vaccine years ago, the recommendation is still to get the full two-dose Shingrix series. Zostavax is no longer available in the United States, and its protection was substantially weaker and shorter-lived. Getting Shingrix after Zostavax is not considered a “booster” in the traditional sense; it is starting a new and better vaccine series. The Advisory Committee on Immunization Practices (ACIP) recommends waiting at least two months after Zostavax before beginning Shingrix, though many providers are comfortable with longer gaps as well.

This is one of the more common points of confusion. People who had Zostavax a decade ago sometimes assume they are still covered, or that one dose of Shingrix on top of their old vaccine is enough. Neither is true. The two vaccines use completely different technologies, and Shingrix’s two-dose series is needed in full regardless of prior Zostavax history.

Who Should Get Vaccinated and at What Age

In the United States, Shingrix is recommended for all adults 50 and older, whether or not they remember having chickenpox. It is also recommended for adults 19 and older who are immunocompromised, since conditions like organ transplant, HIV, certain cancers, or long-term use of immunosuppressive medications sharply raise shingles risk. The virus reactivates when immune defenses weaken, so people whose immune systems are suppressed by disease or medication face a higher baseline threat.²

Across the countries that have adopted Shingrix, there is broad agreement on the core recommendations, though some differences exist in age thresholds and public funding. A review of national guidelines from ten countries, including the United States, Canada, Germany, and the United Kingdom, found that Shingrix was either the preferred or only recommended shingles vaccine in seven of them, with variations in which age groups qualified for publicly funded doses and how special populations were handled.⁸

Real-world effectiveness data confirm that the vaccine works well across a wide age range, though protection is slightly lower in the oldest adults. In a large U.S. study, effectiveness was about 87% among those aged 50 to 79 and about 80% for those 80 and older.¹ That gap is worth noting but should not discourage older adults from getting vaccinated. An 80% reduction in shingles risk is still a major benefit, especially since shingles complications like postherpetic neuralgia become more severe and longer-lasting with age.

Side Effects Are Real but Mostly Short-Lived

One reason so many people skip the second dose is that Shingrix’s side effects can be uncomfortable. The vaccine’s potent adjuvant, which is responsible for its strong and lasting immune response, also causes more noticeable reactions than many other adult vaccines. Soreness at the injection site, fatigue, headache, chills, and fever are all common and can last a day or two. Most people describe it as feeling briefly flu-ish.

Post-marketing safety surveillance based on reports to the U.S. Vaccine Adverse Event Reporting System between October 2017 and April 2024 found that the vast majority of reported events were non-serious, at about 97%.⁹ The most commonly reported side effects in that database were injection-site reactions, fever, chills, headache, and fatigue, which lines up closely with what the clinical trials found. Serious adverse events were rare, and the overall safety profile has remained consistent since the vaccine’s launch.

If the first dose left you feeling rough, expect a similar experience with the second. Some people find the second dose slightly worse, but the side effects still resolve quickly. The discomfort is a sign that your immune system is responding vigorously, which is the whole point. Skipping the second dose because the first one was unpleasant leaves you with less protection against a disease that is far more painful and longer-lasting than a day of post-vaccine aches.

Can You Still Get Shingles After Vaccination

Yes, though it is uncommon. No vaccine prevents infection 100% of the time, and breakthrough cases of shingles after Shingrix have been reported. In rare instances, the timing can be striking. One published case involved a woman in her 60s with a healthy immune system who developed a shingles rash just one week after receiving her Shingrix dose, complete with fever, sweating, headache, and fatigue.¹⁰ Cases like this likely reflect reactivation of latent virus triggered by the immune stimulation from the vaccine itself, not a failure of long-term protection.

When shingles does occur in vaccinated people, it tends to be milder and shorter than in unvaccinated individuals. The risk of the most dreaded complication, postherpetic neuralgia, which is nerve pain that can persist for months or years after the rash heals, is also significantly lower in vaccinated people. So even in the small percentage of cases where the vaccine does not prevent shingles entirely, it still provides meaningful benefit by reducing severity.

What Future Shingles Vaccines Might Look Like

Shingrix has been the dominant shingles vaccine since its approval, but researchers are exploring next-generation options. One area of active development is mRNA-based vaccines for herpes zoster, using the same platform that proved successful for COVID-19 vaccines. Early-stage research in mice has shown that an mRNA vaccine targeting the same viral protein as Shingrix can produce comparable antibody responses at modest doses, and at higher doses can generate even stronger immune reactions.¹¹

This is still preclinical work in animals, far from anything available to the public. But it hints at a future where shingles vaccines might be easier to manufacture, potentially cheaper, and perhaps better suited to boosting if long-term data eventually show that Shingrix protection fades enough to warrant it. An mRNA platform could also make it simpler to adjust formulations or combine shingles protection with other vaccines. For now, Shingrix remains the only game in town for adults seeking shingles protection, and its track record over the past several years has been strong.

Practical Steps if You Are Unsure About Your Status

If you cannot remember whether you completed both Shingrix doses, your pharmacy or doctor’s office can usually check immunization records. Many states maintain immunization registries that track adult vaccinations. If records are truly unavailable, getting an extra dose of Shingrix is not harmful, and your provider may recommend simply proceeding with the series rather than leaving you unprotected.

For people who are immunocompromised, the timing of vaccination relative to treatments like chemotherapy or transplant medications can matter. The vaccine is not live, so it is safe for people with weakened immune systems, but the immune response may be weaker if given during intense immunosuppression. Working with your specialist to find the right window is important for getting the most out of the two-dose series.

Cost is another practical barrier worth addressing. Shingrix is covered by most private insurance plans and by Medicare Part D, though copays vary. The retail price for the full series runs over $300 without insurance, which has been a meaningful obstacle for some people. Programs through vaccine manufacturers and community health centers can sometimes help offset the cost, and the economic argument for vaccination is strong given that a single episode of shingles can involve weeks of misery, multiple doctor visits, prescription antivirals and pain medications, and in some cases long-term nerve damage that affects quality of life for years.

1
Oxford Academic. Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study
2
SpringerLink. VZV T cell-mediated immunity
3
Oxford Academic (The Journal of Infectious Diseases). Correlates of Protection for Herpes Zoster Vaccine: Evaluating Candidate Immunological Variables
4
Elsevier. Cost Effectiveness of a Shingles Vaccine Booster for Currently Vaccinated Adults in the U.S.
5
Taylor & Francis Online. Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019
6
KFF. Who Didn’t Get a Second Shingrix Shot? Implications for Multidose COVID-19 Vaccines
7
Taylor & Francis Online. Predictors of initiation and completion of Shingrix vaccination in immunocompetent adults newly eligible for vaccination from 2018-2024
8
Taylor & Francis Online. A practitioner’s guide to the recombinant zoster vaccine: review of national vaccination recommendations
9
Elsevier. Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017–April 2024
10
Europe PMC. Reactivation of Herpes Zoster After Recombinant Vaccine (Shingrix): A Case Report
11
MDPI (Vaccines). An mRNA Vaccine for Herpes Zoster and Its Efficacy Evaluation in Naïve/Primed Murine Models